Bioniz Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioniz Therapeutics, Inc.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
California-based Bioniz’s lead candidate for cutaneous T-cell lymphoma has been granted orphan drug designation and expects to begin Phase III trials in the second half of 2021. CEO Nazli Azimi explains the science, which originated from her research in academia, and talks about her entrepreneurial journey.
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who is in the spotlight this year.
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
- Large Molecule
- Other Names / Subsidiaries